Prostate cancer prevalence in France

Prostate cancer is the most common cancer among men in France, with nearly 50,000 new cases diagnosed each year. It primarily affects men over the age of 50 and often goes undetected for a long time due to its silent nature.

Prostate cancer's varied progression

The disease can progress slowly, sometimes never requiring treatment, or become aggressive and spread to other parts of the body. This variability makes it challenging to detect and manage, as some tumors may remain harmless while others become life-threatening.

Screening and diagnostic methods

Common diagnostic tools include PSA blood tests and rectal examinations. However, PSA levels can be elevated for reasons other than cancer, or normal even when a tumor is present, making screening a complex and sometimes controversial practice.

Treatment approaches in 2025

Modern treatment strategies focus on precision rather than aggressive intervention. Researchers are exploring advanced methods such as molecular biology and gene editing to develop more effective and targeted therapies for prostate cancer.

Expert opinion on screening

Dr. Ilan Darmon, a Radiation Oncologist, highlights that mass screening for prostate cancer is not currently recommended in France, as it has not been shown to reduce the risk of death from the disease. This underscores the ongoing debate about the benefits and risks of widespread screening.